Our proposed study is the first real-world study to enrich evidence supporting the clinical benefit of using osimertinib with chemotherapy as 1L for the treatment of EGFR mutation-positive in Chinese patients with locally advanced or metastatic NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.